ABSTRACT
BACKGROUND The life course of individuals born very premature is a topic of increasing concern as their neonatal survival has dramatically increased. In a national, prospective, population-based birth cohort, EPIPAGE-2, we observed that amino-acid intakes greater than 3.5 g/kg/day at day 7 after birth were independently associated with higher intelligence quotient at 5 years. As the association between high early amino-acid intake and later HBP in this population is debated, we assessed blood pressure (BP) at 5 years.
METHODS This cohort was initiated in 2011, and approved by ethics committees. Eligible infants were those born between 24 and 29 weeks of gestation and alive on day7 after birth. Infants were distributed in two groups of 717 infants matched on propensity score on whether or not they were exposed to high amino-acid intake (>3.5 g/kg/d at Day7); 455 control term infants were also enrolled. Assessment at 5-year occurred from September 2016 to December 2017. A value > 95th percentile of reference values for age and height defined systolic and/or diastolic HBP.
RESULTS BP at five years of age was assessed for 389 and 385 children in exposed and non-exposed groups. Rates (%) of systolic HBP were 18.0% (95%CI, 14.5 to 22.2), 13.3% (95%CI, 10.3 to 17.0), and 8.5% (95%CI, 6.5 to 11.1) in exposed, non-exposed preterm infants, and term infants, respectively; and 9.0% (95%CI, 6.6 to 12.3), 10.2% (95%CI, 7.5 to 13.6), 5.4% (95%CI, 3.8 to 7.6) % for diastolic HBP, in exposed, non-exposed and term-born groups, respectively. Perinatal characteristics of exposed and non-exposed infants were similar, except for nutrition intake at day3 and day7 after birth. Exposure to high early amino-acid intake, and maximal serum creatinine between day3 and day7 were two independent risk factors for systolic HBP (aOR, 1.60 [95% CI, 1.05 to 2.43] and aOR, 1.59 [95% CI, 1.12 to 2.26] by 50 µmol/L, respectively) but not for diastolic HBP (aOR, 0.84 [95% CI, 0.50 to 1.39] and aOR, 1.09 [95% CI, 0.71 to 1.67] by 50 µmol/L, respectively).
CONCLUSIONS These observations confirm the risk for HBP in young children born very preterm. Higher amino-acid intake and creatinine values in the first week of life were associated with childhood systolic HBP. These results suggest that mechanisms to childhood systolic HBP involves neonatal renal challenge by high amino-acid intake or dysfunction.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03078439
Funding Statement
The EPIPAGE 2 study was supported by grant ANR-11-EQPX-0038 from the National Research Agency (via the French Equipex Program of Investments in the Future); funding from the French Institute of Public Health Research/Institute of Public Health and its partners at the French Health Ministry, the National Institute of Cancer, the National Institute of Health and Medical Research, and the National Solidarity Fund for Autonomy; and funding from the PremUp Foundation. The EPIRMEX study was supported by grant PHRN11- 2011-A00740-41 from the French Health Ministry and the National Institute of Health and Medical Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Assessments occurred only after families had received information and provided written informed consent. This study was approved by the National Data Protection Authority (CNIL DR-2016-290) and by appropriate ethics committees (Consultative Committee on the Treatment of Data on Personal Health for Research Purposes, reference No 16.263; Committee for the Protection of People Participating in Biomedical Research, reference 2016-A00333-48).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data are, in principle, accessible to all research teams, public, French or foreign, subject to authorisation by the cohort Data Access Committee. The new law for modernisation of the French Public Health System voted in 2016 now provides a legal framework for access to and re-use already collected cohort data by complying with ?Reference Methodology MR-004?. Therefore, only non-nominative data defined as having a low re-identification risk are accessible. Moreover, general information on research activities in the institution must be provided to the persons concerned (posting on the premises, entry in the welcome booklet, etc.) To this general information, an individual patient information must be delivered for each project in which the patient is involved or for which the patient data will be treated. As a consequence, each data access request must be submitted to the Epipage 2 Data Access Committee (DAC) that evaluates the research projects based on the following criteria: 1) methodological strengths and weaknesses (feasibility, choice of methods to achieve the objectives) 2) absence of overlap with other ongoing projects, in which case discussions with the different teams are organised 3) relevance of the requested data for the project and respect for confidentiality.
